4.5 Article

Clinical Predictors of the Risk of Early Colectomy in Ulcerative Colitis: A Population-based Study

期刊

INFLAMMATORY BOWEL DISEASES
卷 23, 期 8, 页码 272-277

出版社

OXFORD UNIV PRESS INC
DOI: 10.1097/MIB.0000000000001211

关键词

ulcerative colitis; colectomy; predicators; inflammatory bowel disease

资金

  1. GlaxoSmith Kline
  2. Abbvie
  3. Shire
  4. Merck
  5. Schering-Plough
  6. Abbott Laboratories
  7. Elan Pharmaceuticals
  8. Procter and Gamble
  9. Bristol Meyers Squibb
  10. Millennium Pharmaceuticals
  11. Ferring
  12. Axcan
  13. Jansen
  14. UCB Canada
  15. Pfizer
  16. Pendopharm
  17. Takeda

向作者/读者索取更多资源

Background: A subset of patients with ulcerative colitis (UC) will require colectomy within a few years of diagnosis. Thus, our aim was to determine the clinical predictors of early colectomy among patients with UC who are hospitalized with an acute flare. Methods: Using population-based surveillance (1996-2009), all adults (>= 18 years) hospitalized for UC within 3 years of diagnosis (n = 489) were identified. The primary outcome was a colectomy within 3 years of diagnosis. All medical charts were reviewed. A logistic regression model evaluated clinical variables that predicted colectomy within 3 years of diagnosis, and adjusted odds ratios (ORs) with 95% confidence intervals (CIs) were reported. Results: Among patients admitted to hospital with UC within 3 years of diagnosis, 57.7% underwent colectomy, with the odds of colectomy decreasing by 12% per year. Early colectomy was more likely among patients aged 35 to 64 years versus 18 to 34 years (OR 2.18 [95% CI, 1.27-3.74]), males (OR 2.03 [95% CI, 1.24-3.34]), those with pancolitis (OR 5.38 [95% CI, 3.20-9.06]), and living in rural areas (OR 2.81 [95% CI, 1.49-5.29]). Prescription of infliximab before hospitalization increased odds of surgery (OR 5.12 [95% CI, 1.36-19.30]). Conclusions: Patients hospitalized for UC have a high risk of early colectomy. This is particularly true in middle-aged men, those living in rural areas, and those without response to infliximab.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据